Abstract | BACKGROUND: MATERIALS AND METHODS: RESULTS: CONCLUSION: These results indicate that augmented antitumor activity of the combination treatment was not simply due to the augmentation of direct cytotoxic activity, but was rather an additive effect of the antitumor activities of different mechanisms. They suggest the effectiveness of a combination therapy of MMI-166 with paclitaxel or carboplatin in clinical therapy.
|
Authors | Kanji Hojo, Hideo Maki, Takuko Yamada Sawada, Ryuji Maekawa, Takayuki Yoshioka |
Journal | Anticancer research
(Anticancer Res)
2002 Nov-Dec
Vol. 22
Issue 6A
Pg. 3253-9
ISSN: 0250-7005 [Print] Greece |
PMID | 12530072
(Publication Type: Journal Article)
|
Chemical References |
- Enzyme Inhibitors
- Matrix Metalloproteinase Inhibitors
- N-alpha-(4-(2-phenyl-2H- tetrazole-5-yl) phenyl sulfonyl)-D-tryptophan
- Sulfonamides
- Carboplatin
- Paclitaxel
|
Topics |
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Carboplatin
(administration & dosage, pharmacology)
- Cell Division
(drug effects)
- Drug Synergism
- Enzyme Inhibitors
(administration & dosage, pharmacology)
- Female
- Matrix Metalloproteinase Inhibitors
- Melanoma, Experimental
(drug therapy, enzymology, pathology)
- Mice
- Paclitaxel
(administration & dosage, pharmacology)
- Sulfonamides
(administration & dosage, pharmacology)
|